Introduction
============

The World Health Organization (WHO) recommends that all infants be routinely vaccinated against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, *Hemophilus influenzae* type B (Hib) and measles.[@R1]^,^[@R2] Despite continued gains in global vaccine coverage, WHO estimates that in 2009, 23.2 million children did not receive three doses of diphtheria-tetanus-pertussis (DTP) vaccine, and that 1.7 million children less than 5 y of age died from vaccine-preventable diseases.[@R3]

With the global coverage of DTP3 (three doses of DTP in infancy) now over 80%,[@R3] incorporating additional antigens to DTP vaccines is an effective approach to integrating new vaccines into existing schedules. Combination vaccines reduce the number of injections required to complete vaccination, minimize clinic visits and reduce costs associated with vaccine transport and storage. Importantly, use of combination vaccines improves vaccination coverage rates and the timeliness of vaccination.[@R4]^,^[@R5] DTP has been combined with hepatitis B surface antigen as DTPw-HBV, which may also be mixed with Hib conjugate vaccines (DTPw-HBV/Hib). Combinations of DTPw with Hib and inactivated poliovirus vaccine (IPV) are also available (DTPw-IPV/Hib). No hexavalent vaccine that incorporates all of these antigens (DTPw-HBV-IPV/Hib) is currently available.

Poliomyelitis is a highly infectious disease caused by any one of three poliovirus serotypes. Since the introduction of the Global Polio Eradication Initiative in 1988, the number of poliomyelitis cases has decreased from 350,000 per year in 1988, to 1,783 cases in 2009.[@R3] Much of this gain is attributable to the widespread use of oral live-attenuated poliovirus vaccines (OPV), which have been the cornerstone of polio prevention in most countries since the 1960s. However, in countries where polio has already been eradicated, and in the years following global polio eradication, the risk of vaccine-associated paralytic polio and of polio outbreaks due to circulating vaccine-derived polioviruses means that continued use of OPV is untenable.[@R6] In these settings, population immunity against poliomyelitis will be maintained through IPV.[@R6] Since the production capacity of IPV for worldwide distribution is limited, reduction of the amount of IPV antigen in each vaccine dose would increase capacity and facilitate the shift from OPV to IPV.

A candidate hexavalent DTPw-HBV-IPV/Hib vaccine (GlaxoSmithKline Biologicals \[GSK\]) combines the antigens of two vaccines licensed by GSK: IPV (*Poliorix*™) and DTPw-HBV/Hib (*Zilbrix*™/Hib). The development of the hexavalent vaccine included the feasibility of reducing the quantity of IPV antigens in the DTPw-HBV-IPV/Hib vaccine.

The objectives of this phase II, randomized, partially double-blind dose-range study were to evaluate the immunogenicity, reactogenicity and safety of a booster dose of three DTPw-HBV-IPV/Hib formulations which differed in IPV antigen content (full dose, half-dose and one-third dose, [Table 1](#T1){ref-type="table"}) compared with licensed DTPw-HBV/Hib and IPV administered separately. This was the first administration of the novel DTPw-HBV-IPV/Hib formulation in humans. The study was conducted in healthy toddlers between 12 and 24 mo of age.

###### Composition of study vaccines

  Antigen                          Form 1       Form 1/2        Form 1/3        Control group   
  -------------------------------- ------------ --------------- --------------- --------------- ------------
  Diphtheria toxoid                ≥ 30 IU/ml   ≥ 30 IU/ml      ≥ 30 IU/ml      ≥ 30 IU/ml      \-
  Tetanus toxoid                   ≥ 60 IU/ml   ≥ 60 IU/ml      ≥ 60 IU/ml      ≥ 60 IU/ml      \-
  *Bordetella pertussis* antigen   ≥ 4 IU       ≥ 4 IU          ≥ 4 IU          ≥ 4 IU          \-
  Hepatitis B surface antigen      10 μg        10 μg           10 μg           10 μg           \-
  Polyribosyl ribitol phosphate    2.5 μg       2.5 μg          2.5 μg          2.5 μg          \-
  Poliovirus type 1 (Mahoney)      40 D units   19.60 D units   13.20 D units                   40 D units
  Poliovirus type 2 (MEF-1)        8 D units    3.92 D units    2.64 D units                    8 D units
  Poliovirus type 3 (Saukett)      32 D units   15.68 D units   10.56 D units                   32 D units

All vaccines were manufactured by GSK Biologicals.

Results
=======

Subjects and demography
-----------------------

A total of 312 subjects were enrolled and vaccinated (78 in each group). One subject withdrew consent and failed to complete the study. All other subjects completed the study and all (n = 311) were included in the ATP immunogenicity cohort. The mean age of all subjects was 17.7 mo and 54.2% were males. The study groups were comparable in terms of demographic characteristics at enrolment ([Table 2](#T2){ref-type="table"}).

###### Demographic characteristics of the total vaccinated cohort

  ----------------------------------------------------------------------------------------
                        Form 1\            Form 1/2\   Form 1/3\   Control\    
                        n = 78             n = 78      n = 78      n = 78      
  --------------------- ------------------ ----------- ----------- ----------- -----------
  Age (in months)       Mean               17.4        18.0        17.7        17.5

                        SD                 3.81        2.96        3.38        3.59

                        Range              12--24      12--23      12--23      12--23

  Gender                Female             37 (47.4)   31 (39.7)   35 (44.9)   40 (51.3)

                        Male               41 (52.6)   47 (60.3)   43 (55.1)   38 (48.7)

  Geographic ancestry   South East Asian   78 (100)    78 (100)    78 (100)    78 (100)
  ----------------------------------------------------------------------------------------

Form 1 received DTPw-HBV-IPV (full dose)/Hib vaccine; Form 1/2 received DTPw-HBV-IPV (1/2 dose)/Hib vaccine; Form 1/3 received DTPw-HBV-IPV (1/3 dose)/Hib vaccine; controls received DTPw-HBV/Hib Kft and IPV vaccines concomitantly; N, total number of subjects; value/n, value of considered parameter/number of subjects in a given category; SD, standard deviation.

Immunogenicity
--------------

### Response to poliovirus vaccine

The primary objectives of the study were to demonstrate non-inferiority in terms of immunogenicity, of each DTPw-HBV-IPV/Hib formulation compared with the Control group in terms of anti-polio seroprotection rates and in terms of anti-polio geometric mean antibody titer (GMT) increases (at least a 2-fold increase). Both primary objectives were met for each DTPw-HBV-IPV/Hib group, for each of the three poliovirus types ([Fig. 1](#F1){ref-type="fig"}).

![Comparison between groups in the immune response to poliovirus types 1, 2 and 3 (ATP immunogenicity cohort): (A) difference in seroprotection rates between the control group and each DTPa-HBV-IPV/Hib formulation (Formulations 1--3); (B) GMT ratios (post divided *by* pre-vaccination titers) for anti-poliovirus types 1, 2 and 3. (A) The upper limits of the standardized asymptotic 95% CI on the group difference in the percentage of subjects with anti-poliovirus types 1, 2 and 3 titers ≥ 8 are ≤ 10 (predefined criteria for non-inferiority indicated by bold horizontal line); (B) The lower limits of the two-sided 95% CI on the geometric mean of the individual ratios (post- over pre-vaccination titers) for anti-poliovirus types 1, 2 and 3 antibodies are ≥ 2 (predefined criteria for immunogenicity indicated by bold horizontal line). Form 1 received DTPw-HBV-IPV~(full\ dose)~/Hib; Form 1/2 received DTPw-HBV-IPV~(1/2\ dose)~/Hib; Form 1/3 received DTPw-HBV-IPV~(1/3\ dose)~/Hib; Controls received DTPw-HBV/Hib Kft + IPV.](hvi-8-347-g1){#F1}

Before the booster dose the majority of subjects in each group (between 89.7% and 100%) had seroprotective antibody concentrations against each of the three poliovirus types. One month after the booster dose, between 98.7% and 100% of subjects had seroprotective antibodies against each poliovirus type ([Table 3](#T3){ref-type="table"}). In all groups, post-vaccination GMTs against each poliovirus type increased between 4.2- and 37.9-fold over pre-vaccination levels ([Fig. 1](#F1){ref-type="fig"}).

###### Seroprotection/seropositivity rates and antibody GMCs before and one month post-booster (ATP cohort for immunogenicity)

  Antibody     Group      Pre-vaccination                            Post-vaccination                                                       
  ------------ ---------- ------------------- ---------------------- ---------------------- ------------------- --------------------------- ---------------------------
  Diphtheria   Form 1     78                  88.5 (79.2; 94.6)      0.301 (0.237; 0.382)   78                  100 (95.4; 100)             6.519 (5.460; 7.783)
  Form 1/2     78         88.5 (79.2; 94.6)   0.331 (0.258; 0.424)   78                     100 (95.4; 100)     7.687 (6.112; 9.669)        
  Form 1/3     78         88.5 (79.2; 94.6)   0.330 (0.264; 0.412)   78                     100 (95.4; 100)     8.659 (7.132; 10.514)       
  Control      77         84.4 (74.4; 91.7)   0.374 (0.276; 0.508)   77                     100 (95.3; 100)     6.807 (5.231; 8.858)        
  Tetanus      Form 1     78                  100 (95.4; 100)        0.776 (0.639; 0.942)   78                  100 (95.4; 100)             26.120 (22.650; 30.121)
  Form 1/2     78         98.7 (93.1; 100)    0.766 (0.622; 0.944)   78                     100 (95.4; 100)     31.047 (25.954; 37.139)     
  Form 1/3     78         98.7 (93.1; 100)    0.833 (0.668; 1.038)   78                     100 (95.4; 100)     31.054 (26.837; 35.934)     
  Control      77         98.7 (93.0; 100)    0.932 (0.756; 1.149)   77                     100 (95.3; 100)     24.402 (21.042; 28.298)     
  HBs          Form 1     78                  82.1 (71.7; 89.8)      59.9 (40.3; 89.1)      78                  98.7 (93.1; 100)            2713.4 (1846.9; 3986.2)
  Form 1/2     78         85.9 (76.2; 92.7)   46.9 (32.8; 67.2)      78                     98.7 (93.1; 100)    2395.1 (1630.0; 3519.4)     
  Form 1/3     78         79.5 (68.8; 87.8)   61.9 (42.2; 91.0)      78                     100 (95.4; 100)     3992.8 (2747.2; 5803.1)\*   
  Control      77         90.9 (82.2; 96.3)   88.5 (60.7; 129.0)     77                     100 (95.3; 100)     3484.3 (2452.2; 4950.8)     
  PRP          Form 1     78                  35.9 (25.3; 47.6)      0.134 (0.109; 0.166)   78                  98.7 (93.1; 100)            2.871 (1.797; 4.587)
  Form 1/2     78         34.6 (24.2; 46.2)   0.137 (0.110; 0.172)   78                     97.4 (91.0; 99.7)   2.243 (1.520; 3.310)        
  Form 1/3     78         38.5 (27.7; 50.2)   0.152 (0.118; 0.197)   78                     91.0 (82.4; 96.3)   1.575 (1.065; 2.330)\*      
  Control      77         45.5 (34.1; 57.2)   0.171 (0.130; 0.226)   77                     98.7 (93.0; 100)    3.305 (2.373; 4.603)        
  BPT          Form 1     76                  65.8 (54.0; 76.3)      19.6 (16.4; 23.6)      76                  100 (95.3; 100)             161.8 (143.6; 182.3)\*
  Form 1/2     78         64.1 (52.4; 74.7)   20.1 (16.5; 24.5)      74                     98.6 (92.7; 100)    182.9 (158.0; 211.9)        
  Form 1/3     78         65.4 (53.8; 75.8)   18.9 (15.9; 22.4)      77                     100 (95.3; 100)     211.0 (190.1; 234.2)        
  Control      77         63.6 (51.9; 74.3)   19.5 (16.0; 23.9)      75                     100 (95.2; 100)     194.7 (170.6; 222.4)        
  Polio        Form 1     78                  97.4 (91.0; 99.7)      321.1 (231.2; 446.0)   78                  100 (95.4: 100)             2218.4 (1786.3; 2755.1)\*
  type 1       Form 1/2   78                  89.7 (80.8; 95.5)      219.1 (144.0; 333.6)   78                  98.7 (93.1: 100)            1486.7 (1065.9; 2073.5)\*
               Form 1/3   78                  94.9 (87.4; 98.6)      296.6 (205.1; 428.8)   78                  100 (95.4: 100)             1245.1 (1007.2; 1539.2)\*
               Control    77                  97.4 (90.9; 99.7)      296.9 (213.9; 412.1)   77                  100 (95.3: 100)             3760.2 (2973.7; 4754.7)
  Polio        Form 1     78                  98.7 (93.1; 100)       186.8 (140.1; 249.2)   77                  100 (95.3: 100)             1598.8 (1293.5; 1976.3)\*
  type 2       Form 1/2   78                  96.2 (89.2; 99.2)      152.2 (111.8; 207.3)   78                  100 (95.4: 100)             1056.4 (841.5; 1326.1)\*
               Form 1/3   78                  100 (95.4; 100)        183.4 (146.4; 229.7)   78                  100 (95.4: 100)             966.5 (779.5; 1198.3)\*
               Control    77                  96.1 (89.0; 99.2)      148.0 (112.4; 194.9)   77                  100 (95.3: 100)             2883.2 (2275.2; 3653.8)
  Polio        Form 1     78                  94.9 (87.4; 98.6)      74.5 (56.0; 99.0)      78                  98.7 (93.1: 100)            2820.0 (2129.9; 3733.9)
  type 3       Form 1/2   78                  97.4 (91.0; 99.7)      82.1 (62.1; 108.6)     78                  98.7 (93.1: 100)            2217.7 (1654.0; 2973.4)\*
               Form 1/3   78                  97.4 (91.0; 99.7)      102.1 (77.6; 134.4)    78                  100 (95.4: 100)             1915.8 (1498.1; 2449.8)\*
               Control    77                  90.9 (82.2; 96.3)      79.1 (57.9; 108.1)     77                  100 (95.3: 100)             3626.4 (2618.2; 5022.9)

Form 1 received DTPw-HBV-IPV ~(full\ dose)~/Hib vaccine; Form 1/2 received DTPw-HBV-IPV ~(1/2\ dose)~/Hib vaccine; Form 1/3 received DTPw-HBV-IPV ~(1/3\ dose)~/Hib vaccine; Controls received DTPw-HBV/Hib Kft and IPV vaccines concomitantly; SP/S+, seroprotection defined as concentration ≥ 0.1 IU/ml for diphtheria and tetanus, ≥ 10 mIU/ml for HBs, ≥ 0.15 μg/ml for PRP, ≥ 1:8 for poliovirus, seropositivity defined as ≥ 15 El.U/ml for BPT; GMC/GMT, geometric mean antibody concentration/titer, calculated for all subjects; N, number of subjects with available results; 95% CI, exact 95% confidence interval; \*statistically significant difference post-vaccination between the indicated Form vs. the Control Form (the 95% CI on the adjusted GMC/GMT ratio excluded the value "1").

Anti-poliovirus types 1, 2 and 3 seroconversion rates (seroconversion was defined as post-booster antibody titer ≥ 1:8 in initially seronegative subjects, at least a 4-fold increase in post-booster titer in initially seropositive subjects, or a titer greater than the highest dilution tested \[1:8,192\] in subjects with pre-booster antibody titers \< 8,192) were at least 76.9% in all 4 groups and reached a maximum of 97.4% ([Fig. 2](#F2){ref-type="fig"}). All but two initially seronegative subjects seroconverted after the booster dose (one remained seronegative for poliovirus types 1 and 3, and the other remained seronegative for poliovirus type 3).

![Seroconversion rates for poliovirus types 1, 2 and 3 one month post-booster (ATP immunogenicity cohort). \*Seroconversion was defined as post-booster antibody titer ≥ 1:8 in initially seronegative subjects, at least a 4-fold increase in post-booster titer in initially seropositive subjects, or a titer greater than the highest dilution tested \[1:8192\] in subjects with pre-booster antibody titers \< 8192). Form 1 received DTPw-HBV-IPV~(full\ dose)~/Hib; Form 1/2 received DTPw-HBV-IPV~(1/2\ dose)~/Hib; Form 1/3 received DTPw-HBV-IPV~(1/3\ dose)~/Hib; Controls received DTPw-HBV/Hib Kft + IPV.](hvi-8-347-g2){#F2}

Exploratory analyses indicated that the post-booster GMTs against each poliovirus type were higher in the control group than in each of the DTPw-HBV-IPV/Hib groups, with the exception of poliovirus type 3 in Form 1 group ([Table 3](#T3){ref-type="table"}). Exploratory analyses indicated no differences between groups in poliovirus seroconversion rates with the exception of the seroconversion rate to poliovirus type 1, which was lower in the Form 1/3 group compared with the control group (data not shown). Note that due to the multiplicity of endpoints, statistically significant findings must be interpreted with caution.

### Responses to other vaccine antigens

Before the booster dose the majority of subjects in each group had seroprotective antibody concentrations against diphtheria (range 84.4 to 88.5% ≥ 0.1 IU/ml), tetanus (range 98.7 to 100% ≥ 0.1 IU/ml) and hepatitis B (range 79.5 to 90.9% ≥ 10 mIU/ml; [Table 3](#T3){ref-type="table"}). Pre-booster, between 34.6 and 45.5% were seroprotected against Hib (≥ 0.15 μg/ml) and between 63.6 and 65.8% were seropositive for anti-BPT antibodies (≥ 15 EL.U/ml).

One month after the booster dose all subjects in the 4 study groups had antibody levels consistent with seroprotection against diphtheria and tetanus, and all but two subjects were seroprotected against hepatitis B. The percentage of subjects with seroprotective antibodies against Hib was between 91.0% and 98.7%, and all subjects except one were seropositive for antibodies against BPT.

The secondary objective of the study was to show non-inferiority between each DTPw-HBV-IPV/Hib group and the control group in terms of seroprotection rates against diphtheria, tetanus and hepatitis B, and in terms of antibody GMCs for anti-BPT. All secondary objectives were met (data not shown). Additional exploratory analyses showed no statistically significant differences between groups in terms of seroprotection or seropositivity rates for these antigens.

Post-vaccination anti-PRP GMCs were statistically significantly lower in the Form 1/3 group than the control group, whereas statistically higher GMCs were observed for some DTPw-HBV-IPV/Hib groups for post-vaccination anti-diphtheria, anti-tetanus and anti-HBs antibody GMCs ([Table 3](#T3){ref-type="table"}).

Reactogenicity and safety
-------------------------

All subjects returned diary cards. The majority of subjects (up to 98.7%) reported at least one symptom or adverse event of any type, and between 33.3% and 41.0% of subjects reported an event of grade 3 intensity within the 8-d post-vaccination follow-up period.

Pain, irritability and fever were the most commonly reported solicited symptoms, whereas pain and swelling were the most commonly reported events of grade 3 intensity ([Fig. 3](#F3){ref-type="fig"}). The incidence of solicited local and general symptoms was similar across all 4 groups, as suggested by overlapping 95% CIs in all cases.

![Percentage of subjects reporting solicited local and general symptoms during the 8-d post-vaccination follow-up period (total vaccinated cohort). Grade 3 was defined as: Cried when limb is moved/spontaneously painful (pain); injection site diameter \> 20 mm (redness/swelling); axillary temperature \> 39.0°C (fever); prevented normal daily activities (irritability/fussiness, drowsiness); not eating at all (loss of appetite). Form 1 received DTPw-HBV-IPV~(full\ dose)~/Hib; Form 1/2 received DTPw-HBV-IPV~(1/2\ dose)~/Hib; Form 1/3 received DTPw-HBV-IPV~(1/3\ dose)~/Hib; Controls received DTPw-HBV/Hib + IPV.](hvi-8-347-g3){#F3}

Four large injection site swellings, defined as injection site swelling of diameter \> 50 mm, noticeable diffuse swelling or increased limb circumference, were reported: one subject in each the Form 1 and Form 1/3 groups and two subjects in the Control group.

The percentage of subjects reporting at least one unsolicited symptom during the 31-d follow-up period was, at most, 56.4% across the study groups. Only one grade 3 unsolicited symptom was reported by a subject in the Control group, which was considered by the investigator to be unrelated to vaccination.

Seven subjects reported serious adverse events (SAEs): one in the Form 1 group, three in the Form 1/2 group, two in the Form 1/3 group and one in the Control group. Five SAEs were reports of febrile convulsions, of which two were reported as complex febrile convulsions. All five episodes had an onset between 6 d and 28 d after vaccination. None of the SAEs were considered by the investigator to be causally related to vaccination and all the subjects recovered without sequelae.

Discussion
==========

The present study evaluated a candidate combined hexavalent DTPw-HBV-IPV/Hib vaccine using different IPV antigen dosages for the first time in humans.

All three DTPw-HBV-IPV/Hib formulations met pre-defined criteria in terms of the response to the poliovirus antigens: seroprotection rates were non-inferior to those of the control group, and anti-poliovirus GMTs increased by more than 2-fold from pre to post vaccination. The post-vaccination anti-poliovirus GMTs in the DTPw-HBV-IPV/Hib groups correlated with the IPV antigen content, and was almost always lower than in the Control group. All GMTs were more than 100-fold above the seroprotection cut-off. All anti-poliovirus GMTs were higher than those of a booster dose of OPV administered at the same age and in the same country in a previous study.[@R7] The results suggest that reduction in the IPV antigen content in DTPw-HBV-IPV/Hib is feasible, and deserves further evaluation in other populations, including infants.

Pre-defined non-inferiority criteria in terms of responses to diphtheria, tetanus, hepatitis B and pertussis were also met for each DTPw-HBV-IPV/Hib group compared with the Control group. The results suggest no clinically meaningful impact of the presence of the IPV antigens in the candidate vaccine on the immunogenicity of the DTPw-HBV antigens.

Children enrolled in this study had not received primary vaccination against Hib. Post-vaccination, 91.0 to 98.7% of subjects had seroprotective antibodies against Hib. These seroprotection rates are in the expected range when a Hib vaccine is administered as a single dose in unprimed toddlers. There appeared to be a dose-related effect of IPV on the magnitude of the antibody responses to Hib, with the lowest seroprotection rate and anti-PRP GMC observed following vaccination with DTPw-HBV-IPV/Hib containing the lowest IPV dosage. IPV appears to enhance Hib responses when combined with acellular pertussis vaccines (DTPa).[@R8] The data from the present study suggest a possible dose-related interaction between IPV and Hib immunogenicity.

The safety profile of the 3 DTPw-HBV-IPV/Hib formulations resembled licensed DTPw-HBV/Hib and IPV in terms of the frequency and intensity of adverse reactions after vaccination. The rate of local and general adverse events in this study is consistent with published data following DTPw booster vaccination.[@R9]^,^[@R10] Five subjects experienced febrile convulsion after vaccination. One subject had concurrent pneumonia. Febrile convulsions after DTPw vaccination typically occur within the first 24 h after vaccination.[@R11]^,^[@R12] All cases in the present study began 6 d or later after vaccination, suggesting that they were due to causes other than vaccination.

Potential limitations of the study include the open design with respect to groups that received DTPw-HBV-IPV/Hib and separately administered DTPw-HBV/Hib and IPV which may have introduced bias in the reporting of safety endpoints. Bias in terms of laboratory outcomes is unlikely to have occurred because laboratory staff were blinded to vaccine group during the analysis.

Combination vaccines have an increasingly important role to play in maintaining public acceptance of vaccination, by minimizing the number of injections necessary for full vaccination. Combination vaccines facilitate high levels of vaccination coverage and timely vaccination by reducing the risk of vaccination deferral. Adding new antigens onto existing vaccines with high coverage levels is an efficient way of introducing new antigens into vaccination schedules. Uptake and coverage of the new antigen rapidly increases to the level of the existing vaccine, with good acceptability by parents and vaccine providers. Three formulations of the candidate combined DTPw-HBV-IPV/Hib vaccine were immunogenic when administered as a booster dose to healthy toddlers, with safety and reactogenicity profiles that resembled licensed DTPw-HBV/Hib co-administered with IPV. Further investigation of DTPw-HBV-IPV/Hib for primary vaccination in infants is warranted, including evaluation of formulations containing reduced IPV antigen content.

Methods
=======

Study design and study subjects
-------------------------------

The study was conducted at a single center, the Research Institute for Tropical Medicine, Manila, in the Philippines between May 2010 and September 2010 (113264, [www.clinicaltrials.gov](http://www.clinicaltrials.gov) NCT01106092). Eligible toddlers were between 12 and 24 mo of age, in good health and who had received three doses of poliovirus vaccine as well as other recommended vaccines, via routine primary vaccination procedures during the first year of life.

Subjects were excluded from participation if they had received any investigational drug/vaccine within one month before the booster vaccination; if they had received any non-study vaccine within 30 d prior to booster vaccination, or planned administration during the active study period; if they were immunosuppressed from any cause; if they had a history of infection against any pathogen against which the study vaccines were targeted or had received previous booster vaccination against diphtheria, tetanus, pertussis, poliovirus, hepatitis B and/or Hib.

The study was conducted according to Good Clinical Practice and in accordance with the Declaration of Helsinki. The protocol and associated documents were reviewed and approved by the ethics committees of the participating study center. Written informed consent was obtained from the parents/guardians of all subjects before study entry.

Subjects were randomized (1:1:1:1) to one of four study groups: three groups received DTPw-HBV-IPV/Hib vaccines that differed only in the quantity of poliovirus antigen in each dose ([Table 1](#T1){ref-type="table"}). The study was double-blind with respect to which the DTPw-HBV-IPV/Hib formulation was administered. The control group received commercially available DTPw-HBV/Hib (*Zilbrix*™/Hib) and IPV (*Poliorix*™) vaccines administered as separate injections. Due to the different number of injections given to the control group, subjects knew if they received DTPw-HBV-IPV/Hib or DTPw-HBV/Hib + IPV.

Enrolment was undertaken in a phased manner to evaluate the safety of the new vaccine formulations. During the first phase, a maximum of two subjects were enrolled per day over one month, up to a total of 32 subjects. Randomization was then paused, and safety data were analyzed by an internal Safety Review Committee. No safety concern was raised and hence recruitment was reopened until the target sample size was attained.

Assessment of immunogenicity
----------------------------

Blood samples were collected from all subjects before and one month after the booster dose. Antibodies against diphtheria, tetanus, BPT, hepatitis B surface antigen (anti-HBs) and PRP were measured using standard enzyme-linked immunosorbent assays (ELISA). A microneutralization assay was used to assess antibody titers to the three poliovirus types.[@R13]

Testing for anti-HBs was performed at the Center for Vaccinology Ghent University, Belgium. The poliovirus neutralization assay was undertaken at Biomnis, France. All other assays were performed at GSK Biologicals' laboratory in Belgium using in-house or commercial assays. The serological assays used standardized, validated procedures with adequate controls. Laboratory staff were blinded to vaccine group during the analysis.

Assessment of reactogenicity and safety
---------------------------------------

Local and general symptoms were solicited using diary cards, for 8 d (Day 0--7). Parents/guardians of subjects were advised to contact the investigators in case of any large injection site reaction. Other (unsolicited) symptoms were recorded for 31 d after vaccination and SAEs were recorded for the entire study duration. Completed diary cards were collected at the time of the follow-up blood sample one month after vaccination. Any unreturned diary cards were sought from the subjects' parents/legal guardians via the telephone or any other convenient procedure.

Statistical Analyses
--------------------

Randomization was performed using an SAS program at GSK Biologicals, Belgium. Block randomization (1:1:1:1 ratio) ensured balance between the treatment arms. Treatment allocation was done using a centralized internet randomization system.

The statistician was blind to treatment group during the analysis, although due to the different number of injections, it was possible to ascertain whether subjects received a study vaccine or control. Nevertheless, the statistician was blind to all laboratory results during the analysis.

The primary (non-inferiority) immunogenicity endpoint was performed on the according-to-protocol (ATP) cohort comprising subjects who complied with protocol procedures, had received a booster dose of the study vaccine and had pre- and post-booster blood sampling data available.

A sample size of 78 subjects per group would provide 88% power (Bonferroni adjustment for β) to the overall study, assuming that 10% of subjects dropped out.

The 95% CI for seroprotection/seropositivity status, antibody GMC/GMTs to all antigens, seroconversion status in terms of poliovirus antigens and booster response to the pertussis antigens, one month after booster administration was calculated.

Each DTPw-HBV-IPV/Hib formulation was non-inferior to the control vaccines if the upper limit of standardized asymptotic 95% CI on group difference (control group minus each of the DTPw-HBV-IPV/Hib groups) was ≤ 10% in terms of seroprotection rates to anti-poliovirus 1, 2 and 3, and if the lower limit of the asymptotic 95% CI on geometric mean of individual ratios (post-over pre-booster titers) for antibodies for all three poliovirus types was ≥ 2.

Non-inferiority between groups (secondary objective) would be established if the upper limit of the standardized asymptotic 95% CI on group difference (control group minus each of the DTPw-HBV-IPV/Hib groups) was ≤ 10% in terms of seroprotection rates against diphtheria, tetanus and hepatitis B antigens and upper limit of the 95% CI of the anti-BPT GMC ratio (control group divided by each DTPw-HBV-IPV/Hib group) was ≤ 1.5.

Additional exploratory comparisons between groups were made. Vaccine groups were considered significantly different if the 95% CI for the GMC/GMT ratio (ANCOVA model including the group as fixed effect and the log-transformed pre-booster concentration as covariable) between groups did not contain the value 1, or, if the asymptotic standardized 95% CI for the difference in seroprotection/seropositivity rates between groups did not contain the value 0. Due to the multiplicity of endpoints, statistically significant findings must be interpreted with caution.

Safety and reactogenicity analysis was performed on the total vaccinated cohort comprising all vaccinated subjects. The percentage of subjects reporting symptoms was tabulated with exact 95% CI.

ZILBRIX and POLIORIX are trademarks of GlaxoSmithKline group of companies.
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μg/ml

:   micrograms per milliliter

ATP

:   according to protocol

BPT

:   *Bordetella pertussis*

CI

:   confidence interval

DTPw-HBV-IPV/Hib

:   diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus and *Haemophilus influenzae* type b vaccine

DTPw-HBV/Hib

:   diphtheria-tetanus-whole cell pertussis-hepatitis B- and *Haemophilus influenzae* type b vaccine

EL.U/ml

:   ELISA units per milliliter

GMC

:   geometric mean antibody concentration

GMT

:   geometric mean antibody titer

IPV

:   inactivated poliovirus vaccine

IU/ml

:   international units per milliliter

mIU/ml

:   milli-international units per milliliter

OPV

:   live attenuated oral poliovirus vaccine

PRP

:   polyribosylribitol phosphate

SAE

:   serious adverse event

WHO

:   World Health Organization
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